Thomas Leth Frandsen

Thomas Leth Frandsen

Auto-generated profile, based on publicly available information

Thomas Leth Frandsen

Mary Elizabeth’s Hospital and Juliane Marie Centre, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2017 in Leukemia
Verified
Journal Article
Closed access
NTN Toft
N Toft
HBH Birgens
H Birgens
JAJonas Abrahamsson
Jonas Abrahamsson
LGL Griškevičius
L Griškevičius
HHH Hallböök
H Hallböök
KSK Schmiegelow
K Schmiegelow

1 June 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
KSKjeld Schmiegelow
Kjeld Schmiegelow
AAAndishe Attarbaschi
Andishe Attarbaschi
SBShlomit Barzilai
Shlomit Barzilai
GEGabriele Escherich
Gabriele Escherich
TFThomas Leth Frandsen
Thomas Leth Frandsen
PGPonte di Legno toxicity working group
Ponte di Legno toxicity working group

19 February 2001 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
KBKhalid Bajou
Khalid Bajou
VMVéronique Masson
Véronique Masson
RGRobert D. Gerard
Robert D. Gerard
PSPetra M. Schmitt
Petra M. Schmitt
VAValérie Albert
Valérie Albert
ANAgnes Noel
Agnes Noel
The plasminogen (Plg)/plasminogen activator (PA) system plays a key role in cancer progression, presumably via mediating extracellular matrix degradation and tumor cell migration. Consequently, urokinase-type PA (uPA)/plasmin antagonists are currently being developed for suppression of tumor growth and angiogenesis. Paradoxically, however, high levels of PA inhibitor 1 (PAI-1) are predictive of a poor prognosis for survival of patients with cancer. We demonstrated previously that PAI-1 promoted tumor angiogenesis, but by an unresolved mechanism. We anticipated that PAI-1 facilitated endothelial cell migration via its known interaction with vitronectin (VN) and integrins. However, using adenoviral gene transfer of PAI-1 mutants, we observed that PAI-1 promoted tumor angiogenesis, not by interacting with VN, but rather by inhibiting proteolytic activity, suggesting that excessive plasmin proteolysis prevents assembly of tumor vessels. Single deficiency of uPA, tissue-type PA (tPA), uPA receptor, or VN, as well as combined deficiencies of uPA and tPA did not impair tumor angiogenesis, whereas lack of Plg reduced it. Overall, these data indicate that plasmin proteolysis, even though essential, must be tightly controlled during tumor angiogenesis, probably to allow vessel stabilization and maturation. These data provide insights into the clinical paradox whereby PAI-1 promotes tumor progression and warrant against the uncontrolled use of uPA/plasmin antagonists as tumor angiogenesis inhibitors.

1 September 1999 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
LLLeif R. Lund
Leif R. Lund
JRJohn Rømer
John Rømer
TBThomas H. Bugge
Thomas H. Bugge
BNBoye S. Nielsen
Boye S. Nielsen
TFThomas L. Frandsen
Thomas L. Frandsen
KDKeld Danø
Keld Danø
Retarded wound healing was found in mice deficient in the serine protease precursor plasminogen, as well as in wild‐type mice treated with the metalloprotease inhibitor galardin, but in both cases wound closure was ultimately completed in all mice within 60 days. The expression of several matrix metalloproteases in keratinocytes migrating to cover the wound was strongly enhanced by galardin treatment. However, when plasminogen‐deficient mice were treated with galardin, healing was completely arrested and wound closure was not seen during an observation period of 100 days, demonstrating that protease activity is essential for skin wound healing. The requirement for both plasminogen deficiency and metalloprotease inhibition for complete inhibition of the healing process indicates that there is a functional overlap between the two classes of matrix‐degrading proteases, probably in the dissection of the fibrin‐rich provisional matrix by migrating keratinocytes. Each class alone is capable of maintaining sufficient keratinocyte migration to regenerate the epidermal surface, although this function would normally be performed by both classes acting in parallel. Since there are strong similarities between the proteolytic mechanisms in wound healing and cancer invasion, these results predict that complete arrest of this latter process in therapeutic settings will require the use of inhibitors of both classes of proteases.

22 August 2012 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RRRaheel Altaf Raja
Raheel Altaf Raja
KSKjeld Schmiegelow
Kjeld Schmiegelow
TFThomas Leth Frandsen
Thomas Leth Frandsen

1 September 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
BWBenjamin O Wolthers
Benjamin O Wolthers
TFThomas L Frandsen
Thomas L Frandsen
ABAndré Baruchel
André Baruchel
AAAndishe Attarbaschi
Andishe Attarbaschi
SBShlomit Barzilai
Shlomit Barzilai
KSKjeld Schmiegelow
Kjeld Schmiegelow